Browsing: Vivani

The race to reshape obesity and diabetes treatment is moving beyond weekly injections, and Vivani Medical’s long-acting GLP-1 implant has pushed that story into the spotlight. For investors, the question is how this kind of delivery shift might affect companies tied to GLP-1 drugs, devices, and support therapies. This article looks at 3 stocks from…

Novo Nordisk has taken an interest in a weight-loss implant developed by Californian medtech Vivani Medical, reflecting a broadening of the drugmaker’s strategy to fend off market rivals

Novo Nordisk will conduct a non-exclusive internal evaluation of semaglutide implants prepared by Vivani